Advanced Therapies Week 2026: where CGT innovation meets manufacturing reality

Advanced Therapies Week 2026: where CGT innovation meets manufacturing reality

Anemocyte will attend Advanced Therapies Week 2026, one of the leading US partnering and content events for the cell & gene therapy (CGT) ecosystem, hosted by Phacilitate. The conference will take place at the San Diego Convention Center in San Diego on February 9 – 12, 2026. 

As the sector continues to evolve, the industry’s focus is increasingly shifting from scientific promise to scalable execution – with manufacturing strategy, quality, supply chain robustness, and regulatory readiness becoming decisive factors in moving programs from early development to clinical and commercial stages. Advanced Therapies Week is designed exactly at this intersection, bringing together innovators, developers, manufacturers, and investors to align on what’s next for advanced therapies.

Key themes at the event

Across the week, discussions and meetings will explore topics that shape the future of advanced therapies, including:

  • Cell & gene therapy development and translation to the clinic
  • Manufacturing strategy, scale-up, and industrialization
  • CMC, quality, and regulatory readiness for advanced modalities
  • Enabling technologies and platforms supporting robust production
  • Partnering and collaboration models accelerating development paths 

Anemocyte at Advanced Therapies Week

At Advanced Therapies Week 2026, Anemocyte will share its integrated approach to non-viral manufacturing solutions and discuss how we support organizations working on advanced therapeutic programs.

In addition to the themes traditionally central to the conference, we will highlight:

  • Off-the-shelf plasmid DNA solutions
  • Off-the-shelf mRNA solutions
  • AMCap™ enzymatic capping technology, designed to support high-quality mRNA workflows with consistency and scalability in mind

These capabilities reflect our focus on providing practical, manufacturing-oriented solutions that help developers move faster while maintaining the standards required for regulated environments.

Meet us at our booth 762

Anemocyte will be exhibiting with a dedicated booth. We invite you to stop by to meet the team, exchange perspectives on current manufacturing challenges, and explore how our technologies and platforms can support your next steps – from early development to GMP manufacturing.

1200 900 Anemocyte.com

Anemocyte S.r.l. Single Shareholder Private Limited-Liability Company
Via R. Lepetit, 34 21040 Gerenzano (VA) Italy | Ph: +39 02 99372311 – Fax: +39 02 99372313 | Anemocyte Inc. 1221 Brickell Avenue, Suite 1160 Miami FL 33131

VAT number: 12914940155 | Share capital € 530.000,00 fully paid | R.E.A. 276961